A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Phase 1

Active, not recruiting

• Conditions: Alzheimer's Disease (AD)
• Interventions: Drug: SHR-1707 injection; Drug: Placebo

• Registration Number: NCT06114745
• Lead Sponsor: Atridia Pty Ltd.

Brief Summary

To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-1707 in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD for 26 weeks.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-10-11
• Study First Submitted QC: 2023-10-28
• Study First Posted: 2023-11-02
• Study Start: 2024-04-17
• Status Verified: 2025-03
• Last Update Submitted: 2025-04-13
• Last Update Posted: 2025-04-15
• Primary Completion: 2025-11-07
• Study Completion: 2025-11-07

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

1. Ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial,
2. Male or female aged between 55 years and 85 years (inclusive) at the date of signed consent form.
3. Total body weight of 45~100 kg (inclusive), with a body mass index (BMI) of 19~32 kg/m2 (inclusive)at screening or baseline.
4. The subjects must meet the following clinical criteria for Mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or criteria for mild AD.
5. The subjects should have a stable caregiver who will help the patients to participate in the whole study process.

Exclusion Criteria

1. Cognitive impairment due to other medical or neurological factors (non-AD).

2. History of stroke or transient ischemic attack, seizures, or other unexplained loss of consciousness within the past 1 year.

3. Any psychiatric diagnosis that may interfere with the subject's cognitive assessment.

4. Inability to tolerate MRI examination or have contraindications to MRI examination.

5. Exclusion criteria related to previous or concomitant diseases, as listed in the protocol.

6. Exclusion criteria related to general or laboratory tests, as listed in the protocol.

7. The subject is suicidal according to the investigator's judgment or has committed suicidal behaviour within 6 months prior to the screening period.

8. Severe visual or hearing impairment, unable to cooperate in the scale examination.

9. Patients suspected to be allergic to Aβ antibody drugs and their excipients.

10. Women who are pregnant, or women of childbearing age with positive pregnancy test results or are lactating.

11. History of drug abuse and/or drug addiction within 1 year prior to screening.

13 Use of dual antiplatelet or anticoagulant drugs within 3 months prior to the randomization period or planned during the trial.

14.Have had prior treatment with an anti-amyloid immunotherapy within 1 year prior to randomization.

15. Those who have participated in a clinical trial of any drug or medical device within 3 months prior to screening.

16. Investigators and site-related personnel or other persons directly involved in the implementation of the protocol.

17. Other unspecified reasons that, in the opinion of the investigator or sponsor, make the subject unsuitable for enrolment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Dose level 1 SHR-1707	SHR-1707 injection	SHR-1707 is administered intravenously.
Dose level 1 Placebo	Placebo	Placebo is administered intravenously.

Primary Outcome Measures

Name	Time	Method
Adverse events(AEs)	week 26	To assess the number of patients with adverse events
Baseline in vital signs value	week 26	To assess the number of patients with clinically significant change from baseline in vital signs value
Physical examination	week 26	To assess the number of patients with clinically significant change in physical examination
Laboratory examination	week 26	To assess the number of patients with clinically significant change from baseline in laboratory examination
Baseline in 12-ECG values	week 26	To assess the number of patients with clinically significant change from baseline in 12-ECG values
MRI	week 26	To assess the number of patients with clinically significant change in brain MRI (cerebral edema, microbleeding, etc.)

Secondary Outcome Measures

Name	Time	Method
Aβ positron emission tomography (PET)	week 26	To assess the change from baseline in intracerebral Aβ deposition as measured by brain Aβ positron emission tomography (PET)
Concentrations of SHR-1707	week 26	To assess concentrations of SHR-1707 after multiple doses of administration
Anti-Drug antibody	week 26	To assess the incidence and time of occurrence of anti-SHR-1707 antibodies

Trial Locations

Locations (3)

Liverpool Hospital; 🇦🇺 Sydney, New South Wales, Australia

Southern Neurology; 🇦🇺 Sydney, New South Wales, Australia

Austin Health; 🇦🇺 Melbourne, Victoria, Australia